-

ADDING and REPLACING HeadworX Chooses VoxNeuro Innovation to Enhance Patient Care

Groundbreaking cognitive assessment tool helps improve diagnostic process and outcomes

KITCHENER, Ontario & WATERLOO, Ontario--(BUSINESS WIRE)--Add after eleventh paragraph of release: To get in touch with HeadworX visit headworxclinic.com.

The updated release reads:

HEADWORX CHOOSES VOXNEURO INNOVATION TO ENHANCE PATIENT CARE

Groundbreaking cognitive assessment tool helps improve diagnostic process and outcomes

A leading neurophysiological testing facility has selected VoxNeuro’s innovative technology to provide its patients with more certainty in the diagnosis and treatment of brain conditions, VoxNeuro announced today.

HeadworX, led by neurologist Dr. Abdel Kaleel, MD, M.Sc in Kitchener-Waterloo, is integrating VoxNeuro’s groundbreaking Cognitive Health Assessment™ into its clinical practice.

“Our ability to offer the VoxNeuro Cognitive Health Assessment™ will be an incredible extension to our clinical exam, allowing us to develop a more realistic and complete picture of the patient's road to recovery,” said Dr. Kaleel.

Dr. John F. Connolly, Chief Science Officer and Co-Founder of VoxNeuro, said HeadworX is a much-needed leader in this area.

“Neurology as a profession has been deeply rooted in tradition,” he said. “Dr. Kaleel and his colleagues are future-focused and invested in adopting new and innovative technology that can improve his patient’s medical evaluation and outcomes.”

VoxNeuro’s breakthrough neurotechnology precisely scores cognitive performance by measuring biomarkers in the electrical activity of the brain, much like using a cardiogram to measure the health of the heart. VoxNeuro’s technology is positioned to globally change the way brain health is managed and treated with their rapid, precise scores of cognitive function including memory, information processing, attention and concentration.

This provides valuable data to the diagnostic process, enabling clinicians to make more accurate diagnoses faster. The data also helps to customize treatments and accurately track how well treatments are working overtime, thus helping to ensure the best possible outcomes for patients.

“We welcome the innovation of VoxNeuro because I have long believed that, as a field, we can do a better job of providing patients with the answers they deserve and a clear path to recovery,” says Dr. Kaleel. “With the addition of VoxNeuro, our patients can feel very comfortable that we have the most current means of giving them a true understanding of their condition and an ongoing way to ensure their treatment is working.”

Backed by more than 30 years of global, peer-reviewed scientific research, VoxNeuro’s assessment will also help to ease pressure on the healthcare system as a whole.

“With our growing community population, there is a widening gap for neurological services in Canada,” says Dr. Kaleel. “Many times, patients are over-treated and over-tested and this can place a substantial burden on our healthcare system and subject the patient to unnecessary harm. With the objective data provided by VoxNeuro, we will be better able to determine if a patient’s cognitive concerns warrant further investigations or management options.”

HeadworX serves patients across southwest Ontario, aged from teens to the elderly. The VoxNeuro assessment will augment the clinic’s current array of tools which includes Electromyography (EMG), Electro-encephalography (EEG), Transcranial Doppler (TCD) and Ambulatory Blood Pressure Monitor (ABP).

To get in touch with HeadworX visit headworxclinic.com.

About VoxNeuro – Give your brain a voice

VoxNeuro is backed by more than 30 years of peer-reviewed scientific research and offers the only neurotechnology that scores multiple cognitive functions to support proactive brain health, informed clinical decision-making and customized care. By analyzing the electrical activity of the brain, VoxNeuro scores its cognitive performance in memory, information processing, attention & concentration.

VoxNeuro is headquartered at McMaster Innovation Park in Hamilton, ON, Canada.

Appointments available at VoxNeuro Test Centers. To learn more, follow VoxNeuro on LinkedIn, Twitter, Instagram, Facebook and YouTube or visit www.voxneuro.com.

Ask us about being selected as 1 of 11 emerging growth Canadian Life Sciences Companies by the Government of Canada’s Trade Commissioner Service.

Contacts

Media:
Connie Burke
infinitycomm
416-809-0766
connie@infinitycomm.ca

VoxNeuro LogoVoxNeuro Logo

VoxNeuro


Release Versions

Contacts

Media:
Connie Burke
infinitycomm
416-809-0766
connie@infinitycomm.ca

More News From VoxNeuro

VoxNeuro Raises $3.4M to Accelerate Scaling Its Brain Performance Software Across US Clinics

BOSTON--(BUSINESS WIRE)--VoxNeuro Inc. (“VoxNeuro” or “the Company”), a company that develops leading-edge EEG-based brain performance software, announced the completion of its second financing round with nearly USD $3.4 million raised. The funding round was led by the Company’s largest shareholder, in addition to its strategic investor g.tec, a brain-computer interface and neurotechnology company that serves as VoxNeuro's strategic supplier of EEG hardware. The financing will be used to execut...

VoxNeuro Announces Collaboration with the Canadian Armed Forces and Launch of Clinical Study Measuring Impact of Training-Related Sub-Concussive Exposure

TORONTO--(BUSINESS WIRE)--VoxNeuro Inc. (“VoxNeuro” or the “Company”), a commercial stage Software-as-a-Medical-Device (SaMD) brain health company that analyzes brain biomarkers to assess cognitive function, has announced a new partnership with the Canadian Armed Forces (“CAF”). VoxNeuro and CAF have partnered to study the cognitive effects following intense military training regimens designed to reflect a combat environment and blast exposure. Despite the high prevalence of cognitive issues in...

VoxNeuro Announces Collaboration with Boston University and Launch of Clinical Studies Focusing on Concussion and Alzheimer’s Disease

BOSTON--(BUSINESS WIRE)--VoxNeuro Inc. (“VoxNeuro” or the “Company”), a commercial stage Software-as-a-Medical-Device (SaMD) brain health company that analyzes brain biomarkers to assess cognitive function, announced a new partnership with Boston University (“BU”), a world-class institution and private research university at the forefront of neuroscience and neurotechnology. In partnership with BU, VoxNeuro has launched two studies that will evaluate its cognitive health assessment platform in...
Back to Newsroom